{
    "clinical_study": {
        "@rank": "87357", 
        "arm_group": {
            "arm_group_label": "Treatment (vosaroxin, azacitidine)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and the best dose of vosaroxin when given\n      together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in\n      chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth\n      of cancer cells, either by killing the cells or by stopping them from dividing."
        }, 
        "brief_title": "Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of myelodysplastic syndrome and one of the following:\n\n               -  Cytopenias requiring red blood cell and/or platelet transfusions or neutropenia\n                  (ANC <1 X109/L)\n\n               -  IPSS score of INT-1 or higher at screening\n\n               -  MDS with excess blasts in transformation as defined by FAB criteria (20-29% bone\n                  marrow blasts) or\n\n               -  Chronic myelomonocytic leukemia\n\n          -  Age \u226518 years old\n\n          -  Adequate renal and hepatic function defined as all of the following:\n\n               -  total bilirubin \u2264 2.0 mg/dl, except in cases of Gilbert's disease;\n\n               -  AST and ALT \u22642.5 institutional ULN;\n\n               -  serum creatinine within normal institutional limits or estimated creatinine\n                  clearance \u226560 mL/min/1.73 m2 by the Cockcroft-Gault equation\n\n          -  ECOG performance status \u22642\n\n          -  Ability to understand and willingness to sign an IRB approved written informed\n             consent document (or that of legally authorized representative, if applicable).\n\n          -  Females must be surgically or biologically sterile or postmenopausal or if of\n             childbearing potential, must agree to use an adequate method of contraception during\n             the study until 30 days after the last treatment. Males must be surgically or\n             biologically sterile or agree to use an adequate method of contraception during the\n             study until 30 days after the last treatment. Should a woman become pregnant or\n             suspect she is pregnant while participating in this study, she must inform her\n             treating physician immediately.\n\n          -  Patients may have received up to 3 prior cycles of hypomethylator therapy (i.e.\n             decitabine or azacitidine) prior to enrollment and may have received supportive care\n             measures (growth factors, erythropoietin stimulating agents, transfusion, etc.\n\n          -  Enrolled in HRPO# 201011766 (\"Tissue Acquisition for Analysis of Genetic Progression\n             Factors in Hematologic Diseases\").\n\n        Exclusion Criteria:\n\n          -  Prior treatment with four or more cycles of hypomethylator therapy.\n\n          -  Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the\n             duration of treatment on protocol.\n\n          -  Known seropositivity for or active viral infection with human immunodeficiency virus\n             (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are\n             seropositive because of hepatitis B virus vaccine are eligible.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant and/or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913951", 
            "org_study_id": "201309091"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (vosaroxin, azacitidine)", 
                "description": "Given IV over 10 minutes on Day 1 and 4", 
                "intervention_name": "vosaroxin", 
                "intervention_type": "Drug", 
                "other_name": "voreloxin"
            }, 
            {
                "arm_group_label": "Treatment (vosaroxin, azacitidine)", 
                "description": "Given SC or IV over 15 minutes on days 1-7", 
                "intervention_name": "Azacitidine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vidaza", 
                    "Ladakamycin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 10, 2013", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "mjacoby@dom.wustl.edu", 
                "last_name": "Meagan Jacoby, M.D., Ph.D.", 
                "phone": "314-362-9405"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome", 
        "overall_contact": {
            "email": "mjacoby@dom.wustl.edu", 
            "last_name": "Meagan Jacoby, M.D., Ph.D.", 
            "phone": "314-362-9405"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Meagan Jacoby, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Defined as the highest dose of vosaroxin that results in a DLT in =< 1 of 6 patients graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 4.0", 
            "measure": "MTD of vosaroxin in combination with azacitidine", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "reference": {
            "PMID": "21760592", 
            "citation": "Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec;25(12):1808-14. doi: 10.1038/leu.2011.157. Epub 2011 Jul 15."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913951"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "According to the modified IWG criteria. Summarized as proportion with 95% confidence intervals.", 
                "measure": "Best response (including hematologic improvement)", 
                "safety_issue": "No", 
                "time_frame": "At 3 cycles"
            }, 
            {
                "description": "According to the modified IWG criteria. Summarized as proportion with 95% confidence intervals", 
                "measure": "Best overall response", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 months"
            }, 
            {
                "description": "Graded according to NCI CTCAE v. 4.0. summarized by grade, type and patient.", 
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 7 months"
            }, 
            {
                "description": "According to the modified IWG criteria. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.", 
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 months"
            }, 
            {
                "description": "From the date of first dose of study drug to date of treatment failure, recurrence, or death due to any cause. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.", 
                "measure": "Event-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "From the date of first dose of study drug to disease progression or death from MDS. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "From the date of first documentation of a complete remission (CR) to date of relapse. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.", 
                "measure": "Disease-free survival (DFS)", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "Date of first dose of study drug to the date of death from any cause. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "Serial estimate of biomarker expression will be plotted and summarized over time using means and standard deviations, possibly on a log scale", 
                "measure": "Biomarkers of response to vosaroxin and azacitidine therapy", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}